Everist Genomics has received the U.S. Clinical Laboratory Improvement Amendment certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk of cancer recurrence for patients with early stage colorectal cancer, according to a company news release.
OncoDefender-CRC, which measures the expression of colorectal cancer-specific genes, is a prognostic test capable of predicting the risk of recurrence in patients previously treated with surgical resection of a stage I/II colon cancer tumor or stage I rectal cancer tumor. The company will officially launch the test later this month, according to the news release.
Read the news release about OncoDefender-CRC.
Read other coverage about colorectal cancer prevention:
- ACG, ASGE React to NYTimes 'Letter' About Colonoscopy
- ACOG Urges OB/GYNs to Encourage CRC Screening in Female Patients
- University of Cincinnati Tests Cholesterol Drug to Prevent Recurrence of Colorectal Cancer
OncoDefender-CRC, which measures the expression of colorectal cancer-specific genes, is a prognostic test capable of predicting the risk of recurrence in patients previously treated with surgical resection of a stage I/II colon cancer tumor or stage I rectal cancer tumor. The company will officially launch the test later this month, according to the news release.
Read the news release about OncoDefender-CRC.
Read other coverage about colorectal cancer prevention:
- ACG, ASGE React to NYTimes 'Letter' About Colonoscopy
- ACOG Urges OB/GYNs to Encourage CRC Screening in Female Patients
- University of Cincinnati Tests Cholesterol Drug to Prevent Recurrence of Colorectal Cancer